Stephens Investment Management Group LLC Increases Stock Position in PRA Health Sciences Inc (NASDAQ:PRAH)

Stephens Investment Management Group LLC lifted its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 1.5% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 428,661 shares of the medical research company’s stock after purchasing an additional 6,429 shares during the period. Stephens Investment Management Group LLC owned about 0.65% of PRA Health Sciences worth $42,502,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. GAM Holding AG lifted its stake in shares of PRA Health Sciences by 104.1% in the 1st quarter. GAM Holding AG now owns 8,793 shares of the medical research company’s stock worth $970,000 after purchasing an additional 4,484 shares during the period. Janus Henderson Group PLC lifted its stake in shares of PRA Health Sciences by 13.9% in the 1st quarter. Janus Henderson Group PLC now owns 90,053 shares of the medical research company’s stock worth $9,932,000 after purchasing an additional 10,994 shares during the period. BNP Paribas Arbitrage SA lifted its stake in shares of PRA Health Sciences by 1,559.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 15,166 shares of the medical research company’s stock worth $1,673,000 after purchasing an additional 14,252 shares during the period. OppenheimerFunds Inc. lifted its stake in shares of PRA Health Sciences by 11.9% in the 1st quarter. OppenheimerFunds Inc. now owns 583,614 shares of the medical research company’s stock worth $64,367,000 after purchasing an additional 62,224 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of PRA Health Sciences by 155.1% in the 2nd quarter. SG Americas Securities LLC now owns 45,836 shares of the medical research company’s stock worth $4,545,000 after purchasing an additional 27,869 shares during the period. Hedge funds and other institutional investors own 97.98% of the company’s stock.

Several equities analysts have recently weighed in on PRAH shares. Svb Leerink reiterated a “market perform” rating on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. BidaskClub upgraded shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 24th. Leerink Swann started coverage on shares of PRA Health Sciences in a research note on Tuesday, July 2nd. They issued a “market perform” rating and a $105.00 price objective on the stock. Finally, Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the stock a “hold” rating in a research note on Friday, May 3rd. Eight investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Hold” and a consensus price target of $113.40.

NASDAQ PRAH traded up $2.27 on Thursday, reaching $94.75. 8,979 shares of the stock were exchanged, compared to its average volume of 619,701. PRA Health Sciences Inc has a one year low of $82.12 and a one year high of $121.98. The firm has a market cap of $6.11 billion, a price-to-earnings ratio of 24.04, a PEG ratio of 1.29 and a beta of 1.12. The firm’s 50-day moving average price is $98.26. The company has a debt-to-equity ratio of 1.11, a current ratio of 0.99 and a quick ratio of 0.99.

PRA Health Sciences (NASDAQ:PRAH) last released its earnings results on Wednesday, July 31st. The medical research company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.11. PRA Health Sciences had a net margin of 5.39% and a return on equity of 26.64%. The company had revenue of $763.31 million for the quarter, compared to analysts’ expectations of $764.95 million. During the same quarter last year, the business earned $1.00 EPS. The firm’s revenue was up 5.6% compared to the same quarter last year. As a group, research analysts predict that PRA Health Sciences Inc will post 4.63 earnings per share for the current year.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: How to Invest in the Dividend Aristocrat Index

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.